Hpapi World Congress 2016
High potency APIs, highly potent compounds, HAPI, HPAPI – there are many ways to communicate the hazard but the one thing that remains constant throughout are the high risks when manufacturing these active pharmaceutical ingredients. Experts are seeing a rise in the number of drug products being produced that contain highly potent compounds, but manufacturing processes are not developing accordingly when it comes to increased safety and reduced risk.
Unlike the tobacco industry, the pharmaceutical industry can't put health warnings on the side of highly potent APIs in order to inform the population, as they do on the side of cigarette packets. Yet there are still lessons to be learnt when it comes to protecting personnel, as well as revenue and reputation, from the devastating effects a manufacturing safety breach could have.
Category: Conferences | Science, Health & Medicine | Chemicals
Standard package final price : GBP 1040
Speakers: Marc Abromovitz, Director, Occupational Health and Hygiene, Novartis, Mr Robert Axelsson, Strategic Project Manager, AstraZeneca, Marcel Bührer, Head EH&S / Industrial Hygiene, Johnson & Johnson, Mr Massimiliano Cesarini, Global Sales Manager, Isolation Technology Division, Comecer, Mr Richard Denk, Sales Pharma and Containment Manager, Skan A.G, Philipp Künti, Head of Chemical Manufacturing Mid-Scale, Lonza AG Philipp Künti at HPAPI World Congress, Ester Lovsin Barle, Head of Health Hazard Assessment Center of Excellence, Novartis Ag, Mr Justin Mason-Home, Managing Director, European Operations, SafeBridge Europe, Stefan Peterli, Managing Director, Minakem, Claudio Salvagnini, Commercial Director, Minakem, Anne Toupet, Project Manager, Minakem, Dr Anthony Ward, Sr Director PGS API- Technology Group, Pfizer Ltd, Jan Wren, Senior Occupational Hygienist, SafeBridge Europe Ltd